Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
Objectives To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate response to conventional synthetic DMARDs (csDMARD-IR).Metho...
Saved in:
Main Authors: | Désirée van der Heijde, Yoshiya Tanaka, Paul Emery, Li Xie, Michael Schiff, Gabriella Meszaros, Taeko Ishii, Marta Casillas, Robert A Ortmann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-06-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/5/1/e000898.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baricitinib: key results of long-term use in rheumatoid arthritis
by: N. V. Chichasova, et al.
Published: (2024-08-01) -
Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
by: A. E. Karateev
Published: (2020-09-01) -
The equivocal opposite effects of lower and higher body mass index at diagnosis on radiographic joint damage progression in early rheumatoid arthritis: an inception cohort study over 15 years
by: Sofia Ajeganova, et al.
Published: (2025-07-01) -
BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01) -
ASSOCIATION BETWEEN ULTRASOUND SIGNS OF JOINT INFLAMMATION AND RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: O. G. Alekseeva, et al.
Published: (2016-07-01)